Lizak Carol R. 4
4 · Jaguar Health, Inc. · Filed Apr 2, 2025
Insider Transaction Report
Form 4
Lizak Carol R.
Chief Financial Officer
Transactions
- Purchase
Convertible Promissory Note
2025-03-31$30000.00/sh+5,400$162,000,000→ 5,400 totalExercise: $5.55→ Common Stock (5,400 underlying) - Purchase
Warrant to Purchase Common Stock
2025-03-31+5,400→ 5,400 totalExercise: $5.43From: 2025-03-31Exp: 2030-03-31→ Common Stock (5,400 underlying)
Footnotes (2)
- [F1]The 6% convertible promissory note (the "Note") was issued to pursuant to a securities purchase agreement between Jaguar Health, Inc. (the "Company") and the reporting person dated March 26, 2025 (the "Purchase Agreement"). The Note will mature three months after issuance, and is convertible, at the reporting person's option, in part or in full, into an aggregate of 5,400 shares of the Company's voting common stock, par value $0.0001 per share (the "Common Stock"), at a conversion price of $5.555 per share.
- [F2]As an inducement to enter into the Purchase Agreement, the reporting person received a warrant (the "Warrant") to purchase up to 5,400 shares of Common Stock with an exercise price of $5.43 per share. The Warrant is exercisable immediately upon issuance and will expire on the earlier of (i) five years from the date of issuance, (ii) the consummation of a fundamental transaction and (iii) the consummation of a liquidation event.